Tuesday, August 16, 2022

561.316.3330

Biotechnology News Magazine

Pharma

HERTHENA-Lung02 Phase 3 Trial of Patritumab Deruxtecan Initiated in Patients with EGFR-Mutated Metastatic Non-Small Cell Lung Cancer

Patritumab deruxtecan is currently being evaluated as both a monotherapy and in combination with other anticancer therapies. In addition to the HERTHENA-Lung02 trial, patritumab deruxtecan is being evaluated in HERTHENA-Lung01, a pivotal phase 2 trial in patients with EGFR-mutated locally advanced or metastatic NSCLC previously treated with a EGFR TKI and platinum-based chemotherapy; a phase 1 trial in combination with osimertinib in EGFR-mutated locally advanced or metastatic NSCLC; and a phase 1 trial in previously treated patients with unresectable or metastatic NSCLC. A phase 1/2 trial in HER3 expressing metastatic breast cancer also has been recently completed.

Pharming Announces New ICD-10-CM Code for APDS, a Rare Primary Immunodeficiency

Implemented by the Centers for Disease Control and Prevention, the diagnosis code will accurately identify US patients with APDS, supporting care and research efforts advises Pharming.

Telix APAC Report: Regulatory Progress for Prostate and Kidney Cancer Imaging

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation.

Daewoong Pharmaceutical Co. Revs Up the Growth Engine for Nabota, Achieving the Highest Quarterly Performance Ever

Botulinum toxin solution Nabota achieved 37.1 billion won in sales, a year-on-year increase of 60% from 23.2 billion won, of which exports showed a year-on-year growth of 105% from 14.2 billion won to 29.2 billion won.

MBX Biosciences Receives Orphan Drug Designation for Lead Candidate MBX 2109 for the Treatment of Hypoparathyroidism

MBX 2019 is an investigational long-acting parathyroid hormone (PTH) prodrug. It is currently undergoing evaluation in a Phase 1 randomized, double blind, placebo-controlled trial to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single and multiple ascending doses of MBX 2109 in healthy adult subjects.

Second Innate Pharma NK Cell Engager Selected by Sanofi as Drug Candidate for Development

IPH6401/SAR’514 is a BCMA-targeting NK cell engager using Sanofi’s proprietary CROSSODILE® multi-functional platform, which comprises the Cross-Over-Dual-Variable-Domain (CODV) format notes Innate Pharma.